目次

Chapter- 1: Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Segmentation Breakdown

Chapter- 2: Summary and Highlights
Market Outlook
Report Highlights

Chapter- 3: Market Overview
Myasthenia Gravis
Global Regulatory Structure for Myasthenia Gravis
Pricing and Reimbursement for the Treatment of Myasthenia Gravis
Therapies/Drugs Used to Treat Myasthenia Gravis

Chapter- 4: Market Dynamics
Market Drivers
Market Opportunities
Market Restraints
Risks of Emerging Therapies

Chapter- 5: Market Breakdown by Region
Market Overview

Chapter- 6: Market Breakdown by Type
Market Overview

Chapter- 7: Market Breakdown by Treatment Modality
Introduction

Chapter- 8: Market Breakdown by Type of Product
Monoclonal Antibodies
Cholinesterase Inhibitors
Intravenous Immunoglobulins
Immunosuppressants
Corticosteroids
Table 18 : Global Market for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Figure 8 : Global Market Shares of Myasthenia Gravis Treatments, by Type of Product, 2022

Chapter- 9: ESG Development
Introduction
Environment
Social
Governance
Case Study
Concluding Remarks from BCC Research

Chapter- 10: Emerging Technologies and Developments
Introduction

Chapter- 11: Competitive Intelligence
Overview
Industry Scenario
Company Shares

Chapter- 12: Patent Analysis
Patent Analysis by Manufacturer

Chapter- 13: Pipeline Analysis
Clinical Trials

Chapter- 14: M&A and Venture Funding Outlook
Introduction

Chapter- 15: Company Profiles
ABBVIE INC.
AMYASTHENIA GRAVISEN INC.
ASTELLAS PHARMA INC.
ASTRAZENECA
BAUSCH HEALTH COMPANIES INC.
BAYER AG
BIOGEN INC.
BRISTOL-MYERS SQUIBB CO.
CSL LTD.
DAIICHI SANKYO CO. LTD.
F. HOFFMANN-LA ROCHE AG
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC.
MERCK & CO. INC.
NOVARTIS
PFIZER INC.
SANOFI
SERVIER LABORATORIES
TEVA PHARMACEUTICAL INDUSTRIES LTD.

Chapter- 16: Appendix: Acronyms
Table 100 : Acronyms